Communicating the Value of Pharmacodynamic Modelling in Drug ...
Communicating the Value of Pharmacodynamic Modelling in Drug ...
Communicating the Value of Pharmacodynamic Modelling in Drug ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Q1: What is <strong>the</strong> probability that gemcabene mono<strong>the</strong>rapy<br />
is cl<strong>in</strong>ically superior to ezetimibe 10 mg?<br />
Difference <strong>in</strong> LDL % change frm basel<strong>in</strong>e vs CI1027<br />
Inferior<br />
Equal<br />
Atorvastat<strong>in</strong>: 0<br />
Ref: Atorvastat<strong>in</strong>: 0 + Ezetimibe: 10<br />
Superior<br />
Difference <strong>in</strong><br />
LDL % change frm basel<strong>in</strong>e<br />
20<br />
Gemcabene 10 at a dose <strong>of</strong> 600 mg or more is<br />
0<br />
-10<br />
Gemcabene Inferior Equal Superior<br />
(mg)<br />
300 10.0% 89.9% 0.1%<br />
450 0.0% 53.5% 46.5%<br />
600 0.0% 7.2% 92.8%<br />
900 0.0% 2.8% 97.3%<br />
superior to ezetimibe<br />
Range ± 5%<br />
slide 37<br />
30 May 2008, ARCS<br />
-20<br />
0 200 400 600 800 1000<br />
CI1027<br />
© Pharsight Corporation All Rights Reserved
Change language